Advaxis (ADXS) announced that the FDA has designated lead immunotherapy candidate axalimogene filolisbac (AXAL) for Fast Track review for the adjunctive treatment of high-risk locally advanced cervical cancer. An adjunct (or adjuvant) therapy is administered in addition to the main or initial therapy in order to maximize its effectiveness.